Loading patent…
AssigneeCase Western Reserve University
InventorsMinh Lam, Afshin Dowlati, Hung-Ying Kao, Masaru Miyagi
Estimating the term…
The present disclosure relates generally to the field of medical oncology and, in particular, to methods and kits for identifying and treating neuroendocrine carcinomas, such as small cell neuroendocrine (SCN) tumors. Certain aspects of the present disclosure can include methods of diagnosing a patient with a neuroendocrine carcinoma, methods of determining a survival prognosis in a patient diagnosed with a neuroendocrine carcinoma, compositions that effectively inhibits or decreases an expression level of a hepatocyte cell adhesion molecule 2 (HEPACAM2) biomarker in vivo or ex vivo, and methods of treating a patient having, or suspected of having, a neuroendocrine carcinoma.
A method of diagnosing a patient with a neuroendocrine carcinoma, comprising assaying for an expression level of a hepatocyte cell adhesion molecule 2 (HEPACAM2) biomarker in a biological sample previously obtained from the patient, wherein a detected expression level of the HEPACAM2 biomarker that is higher than a control level of a HEPACAM2 biomarker is indicative of a neuroendocrine carcinoma in the patient.
A method of determining a survival prognosis in a patient diagnosed with a neuroendocrine carcinoma, the method comprising:
A method of treating a patient having, or suspected of having, a neuroendocrine carcinoma, the method comprising administering a therapeutically effective amount of a therapeutic regimen to the patient, wherein the neuroendocrine carcinoma is characterized by an expression level of a hepatocyte cell adhesion molecule 2 (HEPACAM2) biomarker that is higher than a control level of a HEPACAM2 biomarker.
Dependencies are inferred from the claim text.